CELL BIO HUMAN TECH CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,275 KRW | -3.72% |
|
+0.71% | +4.52% |
| 03-26 | Cell Bio Human Tech Co., Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares. | CI |
| 03-26 | Cell Bio Human Tech Co., Ltd authorizes a Buyback Plan. | CI |
Valuation
| Fiscal Period: December | 2023 |
|---|---|
| Capitalization 1 | 37,862 |
| Enterprise Value (EV) 1 | 30,304 |
| P/E ratio | -18.6 x |
| Yield | - |
| Capitalization / Revenue | 1.39 x |
| EV / Revenue | 1.11 x |
| EV / EBITDA | 6.12 x |
| EV / FCF | 15.1 x |
| FCF Yield | 6.63% |
| Price to Book | 0.86 x |
| Nbr of stocks (in thousands) | 9,257 |
| Reference price 2 | 4,090 |
| Announcement Date | 20/03/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 27,570 | 24,103 | 28,588 | 35,161 | 27,545 | 27,324 |
| EBITDA 1 | 10,437 | 5,702 | 6,443 | 7,149 | 5,396 | 4,953 |
| EBIT 1 | 10,080 | 4,720 | 5,292 | 5,610 | 3,535 | 3,149 |
| Operating Margin | 36.56% | 19.58% | 18.51% | 15.95% | 12.83% | 11.53% |
| Earnings before Tax (EBT) 1 | 10,051 | 4,960 | 4,789 | 4,479 | 3,541 | -811.8 |
| Net income 1 | 9,009 | 4,505 | 4,187 | 3,131 | 2,890 | -1,857 |
| Net margin | 32.68% | 18.69% | 14.65% | 8.91% | 10.49% | -6.8% |
| EPS 2 | 739,601 | 515.0 | 520.0 | 396.7 | 412.8 | -220.0 |
| Free Cash Flow 1 | 49.33 | 1,649 | -10,510 | 2,734 | -1,020 | 2,010 |
| FCF margin | 0.18% | 6.84% | -36.76% | 7.78% | -3.7% | 7.35% |
| FCF Conversion (EBITDA) | 0.47% | 28.91% | - | 38.25% | - | 40.58% |
| FCF Conversion (Net income) | 0.55% | 36.6% | - | 87.32% | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 08/04/19 | 02/04/20 | 30/03/21 | 31/03/22 | 29/03/23 | 20/03/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 8,025 | 29,402 | 11,953 | 6,728 | 1,663 | 7,558 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 49.3 | 1,649 | -10,510 | 2,734 | -1,020 | 2,010 |
| ROE (net income / shareholders' equity) | 57.3% | 13.1% | 9.19% | 7.51% | 7.52% | -4.49% |
| ROA (Net income/ Total Assets) | 35% | 8.14% | 6.77% | 6.62% | 4.25% | 3.97% |
| Assets 1 | 25,750 | 55,317 | 61,830 | 47,320 | 68,052 | -46,786 |
| Book Value Per Share 2 | 1,669,076 | 5,731 | 6,097 | 4,059 | 4,528 | 4,766 |
| Cash Flow per Share 2 | 455,770 | 1,326 | 873.0 | 1,990 | 642.0 | 438.0 |
| Capex 1 | 1,515 | 2,802 | 13,230 | 3,725 | 360 | 628 |
| Capex / Sales | 5.5% | 11.63% | 46.28% | 10.59% | 1.31% | 2.3% |
| Announcement Date | 08/04/19 | 02/04/20 | 30/03/21 | 31/03/22 | 29/03/23 | 20/03/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +4.52% | 27.3M | |
| +25.14% | 7.5B | |
| +8.01% | 3.65B | |
| +21.29% | 2.36B | |
| +6.17% | 2.29B | |
| +7.00% | 2.26B | |
| +73.81% | 2.22B | |
| +3.41% | 1.69B | |
| +32.65% | 1.66B | |
| +1.95% | 1.66B |
- Stock Market
- Equities
- A318160 Stock
- Financials Cell Bio Human Tech Co., Ltd
